ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 424

Re-Establishment of Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, in Rheumatoid Arthritis Patients after Temporary Discontinuation

Jeffrey Kaine1, John Tesser2, Ryan DeMasi3, Liza Takiya3, Lisy Wang4, Mark Snyder3, Haiyun Fan4 and Jürgen Wollenhaupt5, 1Sarasota Arthritis Research Center, Sarasota, FL, 2Arizona Arthritis & Rheumatology Associates, Glendale, AZ, 3Pfizer Inc, Collegeville, PA, 4Pfizer Inc, Groton, CT, 5Schön-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Assessment, C Reactive Protein, Rheumatoid arthritis (RA), tofacitinib and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We assessed tofacitinib efficacy and safety after temporary discontinuation and reinitiation of therapy in patients (pts) with RA.

Methods: Data were from a randomized, parallel-group (grp), controlled, open‑label vaccine sub-study in pts with RA participating in a long-term extension study (NCT00413699). Pts were aged ≥18 years with active RA and had received tofacitinib 10 mg twice daily (BID) for ≥3 months. The sub-study included 2 treatment (tx) grps: ‘continuous tx’ (tofacitinib 10 mg BID ± methotrexate [MTX]) and ‘interrupted tx’ (tofacitinib withdrawn for 2 weeks post-randomization [Day 1–15; Visits 1–3], then tofacitinib 10 mg BID reinitiated ± MTX at Visit 3); randomization was stratified by MTX use. All pts received pneumococcal and influenza vaccines on Day 8 (Visit 2; vaccine titers reported previously1). Blood samples were taken on Days 8, 15 (Visit 3), and 43 (Visit 4). Efficacy endpoints included change from baseline (CFB) in CRP, HAQ‑DI, and DAS28-4(ESR) at each visit. A mixed-effects model with repeated measures was used to evaluate treatment effect at each visit. Efficacy analyses were exploratory, with no multiplicity adjustments. P<0.05 was considered as statistically significant.

Results: Of the 199 pts in this analysis (continuous, n=100; interrupted, n=99), 117 received concomitant MTX. At study baseline (BL) in the continuous and interrupted grps, respectively: 81.8/83.8% of total pts were white, 84.8/86.9% were female, and mean age was 55.0/53.9 years. CRP, HAQ-DI, and DAS28-4(ESR) BL values were generally similar between groups. At Day 8, mean CRP and DAS28-4(ESR) significantly increased from BL for pts receiving interrupted vs continuous tx; HAQ-DI values were similar between grps (Figure). At Day 15, mean CRP, HAQ-DI, and DAS28-4(ESR) significantly increased from BL for pts receiving interrupted vs continuous tx. After tofacitinib reinitiation for 28 days (Day 43), CFB in CRP, HAQ-DI, and DAS28-4(ESR) were similar between grps and approached BL levels. Adverse events (AEs) were experienced by 35.4% and 49.5% of pts receiving interrupted and continuous tx, respectively. The most frequent treatment-emergent AEs were bronchitis and upper respiratory tract infection (each AE: 6 pts) and vaccination-related immunisation reaction, myalgia, and rash (each AE: 5 pts). Serious AEs occurred in 3 pts (3%) in each grp. In total, 1 pt (1%) in the interrupted grp discontinued due to study drug-related AEs; no pts discontinued due to disease flare.

Conclusion: Efficacy of tofacitinib 10 mg BID can be re-established following a temporary (2 weeks) tx discontinuation in pts with RA. Pts receiving continuous tx maintained efficacy throughout the study. Further investigations are required.

Reference:

1.     Winthrop KL et al. Ann Rheum Dis 2016; 75: 687-695.

 


Disclosure: J. Kaine, Pfizer Inc, Bristol-Myers Squibb, 8; J. Tesser, Pfizer Inc, 2,Pfizer Inc, 5,Pfizer Inc, 8; R. DeMasi, Pfizer Inc, 1,Pfizer Inc, 3; L. Takiya, Pfizer Inc, 1,Pfizer Inc, 3; L. Wang, Pfizer Inc, 1,Pfizer Inc, 3; M. Snyder, Pfizer Inc, 1,Pfizer Inc, 3; H. Fan, Pfizer Inc, 1,Pfizer Inc, 3; J. Wollenhaupt, Pfizer Inc, 1,Pfizer Inc, 8.

To cite this abstract in AMA style:

Kaine J, Tesser J, DeMasi R, Takiya L, Wang L, Snyder M, Fan H, Wollenhaupt J. Re-Establishment of Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, in Rheumatoid Arthritis Patients after Temporary Discontinuation [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/re-establishment-of-efficacy-of-tofacitinib-an-oral-janus-kinase-inhibitor-in-rheumatoid-arthritis-patients-after-temporary-discontinuation/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/re-establishment-of-efficacy-of-tofacitinib-an-oral-janus-kinase-inhibitor-in-rheumatoid-arthritis-patients-after-temporary-discontinuation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology